Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei

Annals of Clinical and Laboratory Science

Volumn 34, Issue 3, 2004, Pages 271-276

  Moon, Yeonsook ^a   Park, Gyeongsin ^b   Kim, Yonggoo ^b   Kim, Myungshin ^b   Lim, Jihyang ^b   Pai, Soo Hwan ^a   Lee, Eun Jung ^b   Kang, Chang Suk ^b   Han, Kyungja ^b  

^a Inha University School of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

As2O3; Cancer chemotherapy; Carcinoma cell lines; Carcinomatosis peritonei

Indexed keywords

ARSENIC TRIOXIDE; TRYPAN BLUE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; AUTOPSY; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CARCINOMATOUS PERITONITIS; CELL STRAIN LOVO; CELL STRAIN OVCAR 3; CELL STRAIN PA 1; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; TUMOR CELL DESTRUCTION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; FEMALE; NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; TUMOR CELL LINE;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXIDES; PERITONEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444290631     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Byrd DM, Roegner ML, Griffiths JC, Lamm SH, Grumski KS, Wilson R, Lai S. Carcinogenic risks of inorganic arsenic in perspective. Int Arch Occup Environ Health 1996;68:484-494.
2. 3 induced NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML protein. Blood 1996;88:1052-1061.
3. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chinese J Hematol 1996;17:58-62.
4. Zhang W, Ohnishi K, Shigeno K, Fujisawa, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R. The induction of apoptosis on the cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-1391.
5. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down regulation of Bcl-2 protein. Br J Haematol 1998;102:1055-1060.
6. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
7. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002;7(suppl 1):14-9.
8. Zhang TC, Cao EH, Lee JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;5:1258-1263.
9. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-4964.
10. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000;5:155-158.
11. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002;13:293-300.
12. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;61:5432-5440.
13. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
14. Doyle A, Griffiths JB, Newell DG. Trypan blue exclusion method for cell viability estimation. In: Cell and Tissue Culture: Laboratory Procedures. Wiley, London, 1993;4B: 5.2.
15. Snow ET. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 1992;53:31-65.
16. Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to arsenic. Clincal course in four patients with electrophysiological and histological studies. J Neurol Sci 1977;32:437-451.
17. Greenburg SA. Acute demyelinating polyneuropathy with arsenic ingestion. Muscle Nerve 1996;19:1611-1613.
18. Dittrich C, Panzer S, Lomoschitz KH, Vycudilik W. Acute self-poisoning with arsenic and treatment with BAL. Wien Klin Wochenschr 1978;90:796-799.
19. 3. Arch Toxicol 1995;69:712-717.
20. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
21. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81:796-799.
22. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang Zy, Chen Z, de The H. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978-3983.
23. Muller S, Miller WH Jr, Dejean A. Trivalent antimonials induce degradation of the PML-RARα oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 1998;92:4308-4316.
24. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:7767-7780.
25. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, Deblasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Eng J Med 1998;339:1341-1348.
26. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268-277.
27. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.